Many PE Teams Embraced Mechanical Thrombectomy Early On: PERT Registry

Why It Matters

The rapid, data‑light adoption of thrombectomy reshapes PE care pathways and could affect outcomes and cost across diverse health systems.

Key Takeaways

• Mechanical thrombectomy grew 18% yearly, surpassing thrombolysis by 2021
• Adoption higher in older, high‑acuity, male patients
• Midwest centers use thrombectomy more than Northeast
• Practice variation driven by expertise, device access, finances
• Randomized trials needed to standardize PE treatment decisions

Pulse Analysis

The surge in mechanical thrombectomy for acute pulmonary embolism illustrates how interventional cardiology can outpace formal evidence generation. Early adopters, often embedded within Pulmonary Embolism Response Teams (PERT), embraced the technology before the STORM‑PE and PEERLESS trials were completed, citing faster clot removal and perceived safety in high‑risk patients. This real‑world momentum is captured in the PERT Consortium Registry, which tracked nearly 3,000 intermediate‑ and high‑risk cases across 48 U.S. centers, revealing an 18% annual increase in thrombectomy use.

Patient‑level analysis shows that older age, vasopressor dependence, ECMO support, clot‑in‑transit, and saddle‑type emboli drive clinicians toward mechanical thrombectomy, while younger, female, and lower‑acuity patients still receive catheter‑directed thrombolysis. Geographic disparities are stark: the Midwest reports the highest adoption rates, whereas several Northeast and Southern states lag behind, reflecting differences in device availability, operator expertise, and institutional financial models. Such heterogeneity underscores the influence of local culture over uniform clinical guidelines.

The implications are twofold. First, without randomized controlled trial data, the field risks entrenched practice patterns that may not align with optimal patient outcomes. Second, recent joint AHA/ACC guidelines that endorse PERT teams provide a framework for multidisciplinary decision‑making, but they stop short of prescribing a specific therapeutic algorithm. As randomized evidence emerges, it will be crucial to harmonize practice, integrate bleeding‑risk assessments, and ensure equitable access to advanced PE interventions across all regions.